| DB ID | MyCo_4913 |
| Title | Clinical importance of cerebrospinal fluid protein levels in HIV-associated cryptococcal meningitis: Insights from a prospective cohort study in Uganda |
| Year | 2024 |
| PMID | 39419774 |
| Fungal Diseases involved | Cryptococcal meningitis |
| Associated Medical Condition | HIV-AIDS |
| Genus | Cryptococcus |
| Species | spp. |
| Organism | Cryptococcus spp. |
| Ethical Statement | Ethical approvals for both clinical trials were granted from the Mulago Hospital Research and Ethics Committee, the Uganda National Council of Science & Technology, and the University of Minnesota Institutional Review Board. All par- ticipantsorsurrogatesprovidedwrittenconsentforstudypar- ticipation. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Thi7 |
| Biomarker Full Name | Thi7 |
| Biomarker Type | Predictive |
| Biomolecule | Protein |
| Geographical Location | Uganda |
| Cohort | Here analyzed data from 890 adults with HIV-associated cryptococcal meningitis randomized into two clinical trials in Uganda between 2015 and 2021. |
| Cohort No. | 890 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | Luminex Discovery Assay |
| ELISA kits | None |
| Assay Data | Human Lu- minex Discovery Assay (R&D systems, Minneapolis, MN, USA). |
| Validation Techniques used | Luminex Discovery Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
